Stock IBRX IMMUNITYBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
7.205 USD -5.82% Intraday chart for ImmunityBio, Inc. -18.48% +40.14%
May. 09 ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ImmunityBio - Connecting the Dots of ANKTIVA's Triangle Offense, A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
AQ
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
BU
ImmunityBio: Q1 Earnings Snapshot
AQ
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment
MT
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
BU
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline
MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline
MT
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
BU
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types
CI
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association
AQ
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
BU
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline
MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating
MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
MT
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval
PU
Transcript : ImmunityBio, Inc. - Special Call
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
AQ
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. News ImmunityBio, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW